Treatment of Kawasaki Disease using Locally Product Intravenous lmmunoglobulint
CHAISIT SANGTAWESIN, MD*, THA WATCHAI KIRA WITA YA, MD*, THANARAT LAY ANGKOOL, MD*, WIPAJAREE NAWASIRI, BSc**, NA WAPORN VIMOLSARA WONG, MSc**.
Affiliation : * Pediatric Cardiology Unit, **Department of Pharmacology, Queen Sirikit National Institute of Child Health, Bangkok 10400, Thailand. t The Thai Red Cross Society Product
Objective : To determine the initial treatment response and prevalence of CAA in KD treated with a high dose (2 g/kg) of Thai Red-Cross IVIG.
Patients and
Method : All patients with a diagnosis of KD who had initial treatment with 2 g/kg of Thai Red-Cross IVIG at Queen Sirikit National Institute of Child Health from December 2001 to February 2003 were reviewed retrospectively.
Results : All 22 cases ( 100%) had good response to a single treatment with a high dose of IVIG. The only patient who did not complete the IVIG treatment had a severe reaction following the administration of the drug and needed discontinuation and intervention. During the convalescent phase, there were only 2 cases (9.09%) with CAA in the first month and 1 case (4.55%) at the 3-month follow up. This only case with CAA at 3 months had multiple aneurysms at the left main and left anterior descending coronary arteries. No giant aneurysms were found in the present study.
Conclusion : The efficacy of a high dose (2 glkg) of Thai Red-Cross IVIG in Kawasaki disease is excellent. However, the severe reaction in one patient needs further surveillance.
Keywords : Kawasaki, Using Locally Product
